Back to top
more

Akero Therapeutics (AKRO)

(Delayed Data from NSDQ)

$29.76 USD

29.76
720,241

-1.21 (-3.91%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $29.00 -0.76 (-2.55%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Are Medical Stocks Lagging GSK PLC Sponsored ADR (GSK) This Year?

by Zacks Equity Research

Here is how GSK (GSK) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.

Here's Why Akero Therapeutics, Inc. (AKRO) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Akero Therapeutics, Inc. (AKRO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Akero Therapeutics, Inc. (AKRO) and Perspective Therapeutics (CATX) have performed compared to their sector so far this year.

Ekta Bagri headshot

Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback

by Ekta Bagri

Acquisition and pipeline updates from Bristol Myers (BMY) and Akero Therapeutics (AKRO) are in focus in the biotech sector.

Akero (AKRO) Slumps 63% on Mixed Results From NASH Study

by Zacks Equity Research

Data from a mid-stage study shows that Akero Therapeutics' (AKRO) lead candidate failed to achieve statistical significance in its primary endpoint of fibrosis improvement in cirrhotic NASH patients.

Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA

by Zacks Equity Research

Madrigal (MDGL) gains as new drug application for resmeritom to treat nonalcoholic steatohepatitis gets accepted by the FDA in the United States.

Theseus (THRX) Falls 72% on Decision to Discontinue GIST Study

by Zacks Equity Research

Theseus (THRX) announces the discontinuation of enrollment in its phase I/II study of THE-630 in patients with gastrointestinal stromal tumors due to observed adverse reactions. The stock falls 72%.

Apellis (APLS) Stock Surges 62% in 6 Months: Here's Why

by Zacks Equity Research

Apellis' (APLS) shares have rallied 62% over the past six months due to the approval of Syfovre (pegcetacoplan injection) in February. An encouraging uptake of its first marketed product, Empaveli, has further bolstered the stock value.

Acadia (ACAD) Expands Existing Licensing Deal With Neuren

by Zacks Equity Research

Acadia (ACAD) rises 23% for extending its existing licensing agreement with Neuren to include ex-North American rights to trofinetide along with the global rights to a different developmental candidate.

Recursion (RXRX) Up on $50M NVDA Investment for AI Drug Discovery

by Zacks Equity Research

Recursion (RXRX) soars on receiving an investment worth $50 million from Nivida for drug development using artificial intelligence.

Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301

by Zacks Equity Research

Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301.

ADC Therapeutics (ADCT) Dips on Halting Zynlonta Study

by Zacks Equity Research

ADC Therapeutics (ADCT) pauses patient enrollment in a mid-stage study evaluating Zynlonta in combination with rituximab, for patients with previously untreated diffuse large B-cell lymphoma who are unfit or frail.

Bristol Myers (BMY) Reports Positive Data From Urothelial Cancer Study

by Zacks Equity Research

Bristol Myers (BMY) meets its dual primary endpoint in the late-stage expansion study of Opdivo for the treatment of unresectable or metastatic urothelial carcinoma.

Panbela (PBLA) Up 11% on Update From Pancreatic Cancer Study

by Zacks Equity Research

Panbela (PBLA) rises 11% on a positive recommendation from an independent board reviewing safety data from a late-stage study of ivospemin in the treatment of pancreatic cancer.

Novavax (NVAX) to Receive $350M From Canada, Stock Rises 30%

by Zacks Equity Research

Novavax (NVAX) is set to receive $350M from the Canadian government for forfeited Covid-19 vaccine doses per an amendment to the original purchase agreement between the parties. The stock rises 30%.

Infinity Pharma (INFI) Stock Up on Advancing Cancer Study

by Zacks Equity Research

Infinity Pharma (INFI) provides insights on the phase II MARIO-8 study design. The study will evaluate eganelisib for squamous cell cancer of the head and neck.

Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study

by Zacks Equity Research

Axsome (AXSM) doses its first patient in the late-stage, label expansion study of solriamfetol for treating attention deficit hyperactivity disorder.

ASLAN (ASLN) Down 25% on Mixed Results From Skin Disease Study

by Zacks Equity Research

ASLAN (ASLN) reports mixed results from a mid-stage study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis. The stock price of the company fell by 25%.

Ultragenyx (RARE) Doses First Patients in Bone Disease Studies

by Zacks Equity Research

Ultragenyx (RARE) announces dosing the first patients in its phase III studies evaluating setrusumab (UX143) in young adult and pediatric patients with osteogenesis imperfecta.

Vertex (VRTX) Gets Nod in EU for Orkambi Expanded Indication

by Zacks Equity Research

Vertex's (VRTX) Orkambi gets approval from the European Commission in the EU for the treatment of cystic fibrosis in patients (aged 1 to <2 years) who have two copies of the F508del mutation.

CRISPR (CRSP) Shares Rise 24% in the Last Quarter: Here's Why

by Zacks Equity Research

Shares of CRISPR (CRSP) surge 24% in the last quarter after the company, along with Vertex, provides positive regulatory updates on exa-cel BLAs in SCD and TDT treatment.

Here's Why You Should Add Alkermes (ALKS) to Your Portfolio

by Zacks Equity Research

Alkermes (ALKS), a top-ranked stock, has a diverse portfolio of neurological therapies. Its proprietary products are witnessing incremental sales.

Aurinia (AUPH) Up on Paving the Way for a Potential Buyout

by Zacks Equity Research

Aurinia (AUPH) surges as management decides to explore strategic business options, including potential sale or a merger.

Alnylam (ALNY) Announces FDA Committee Onpattro sNDA Review Date

by Zacks Equity Research

Alnylam (ALNY) reports that the FDA has set Sep 13, 2023, as the day for the meeting of the Advisory Committee to review its sNDA application for patisiran in treating the cardiomyopathy of ATTR amyloidosis.

Kintara (KTRA) Rises 41% on $2M Grant for Breast Cancer Therapy

by Zacks Equity Research

Kintara (KTRA) receives a $2 million grant from the National Institutes of Health to develop its breast cancer treatment candidate, REM-001. The stock surges 41%.